Cargando…
Dexamethasone vs methylprednisolone high dose for Covid-19 pneumonia
BACKGROUND: There is no effective therapy for the severe acute respiratory syndrome by coronavirus 2 (SARS-CoV2) responsible for the Coronavirus disease 2019 (Covid-19). To date, dexamethasone has shown a decrease in mortality in patients who require oxygen, especially those with invasive mechanical...
Autores principales: | Pinzón, Miguel Alejandro, Ortiz, Santiago, Holguín, Héctor, Betancur, Juan Felipe, Cardona Arango, Doris, Laniado, Henry, Arias Arias, Carolina, Muñoz, Bernardo, Quiceno, Julián, Jaramillo, Daniel, Ramirez, Zoraida |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8148307/ https://www.ncbi.nlm.nih.gov/pubmed/34033648 http://dx.doi.org/10.1371/journal.pone.0252057 |
Ejemplares similares
-
Clinical outcome of patients with COVID-19 Pneumonia treated with corticosteroids and colchicine in Colombia
por: Pinzón, Miguel Alejandro, et al.
Publicado: (2021) -
Differences in the Clinical Outcome of Osteomyelitis by Treating Specialty: Orthopedics or Infectology
por: Arias Arias, Carolina, et al.
Publicado: (2015) -
Intratympanic dexamethasone injection vs methylprednisolone for the treatment of refractory sudden sensorineural hearing loss
por: Berjis, Nezamoddin, et al.
Publicado: (2016) -
Dexamethasone/hydrocortisone/methylprednisolone: Disseminated cryptococcosis following off label use of dexamethasone, hydrocortisone and methylprednisolone: case report
Publicado: (2022) -
Skeletal Muscle Response to Deflazacort, Dexamethasone and Methylprednisolone
por: Fappi, Alan, et al.
Publicado: (2019)